Published in Genes Dev on April 15, 2011
The Hippo pathway and human cancer. Nat Rev Cancer (2013) 5.17
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med (2014) 2.03
The DREAM complex: master coordinator of cell cycle-dependent gene expression. Nat Rev Cancer (2013) 1.93
DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev (2011) 1.82
MiR-93 enhances angiogenesis and metastasis by targeting LATS2. Cell Cycle (2012) 1.74
The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle. Cell Div (2012) 1.46
Organ size control by Hippo and TOR pathways. Curr Biol (2012) 1.45
Pumilio facilitates miRNA regulation of the E2F3 oncogene. Genes Dev (2012) 1.36
Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis. J Biol Chem (2013) 1.27
Newly identified aspects of tumor suppression by RB. Dis Model Mech (2011) 1.24
Conserved RB functions in development and tumor suppression. Protein Cell (2011) 1.15
Regulation and functions of mammalian LATS/NDR kinases: looking beyond canonical Hippo signalling. Cell Biosci (2013) 1.09
Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control. Cell Cycle (2012) 1.05
The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl. Cell Death Differ (2013) 1.04
Actin cytoskeletal remodeling with protrusion formation is essential for heart regeneration in Hippo-deficient mice. Sci Signal (2015) 0.95
Comparative expression profiling identifies differential roles for Myogenin and p38α MAPK signaling in myogenesis. J Mol Cell Biol (2012) 0.91
Post-transcriptional gene expression control by NANOS is up-regulated and functionally important in pRb-deficient cells. EMBO J (2014) 0.90
What do mechanotransduction, Hippo, Wnt, and TGFβ have in common? YAP and TAZ as key orchestrating molecules in ocular health and disease. Exp Eye Res (2013) 0.90
The role of the hippo pathway in melanocytes and melanoma. Front Oncol (2013) 0.90
Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway. Mol Cancer Res (2015) 0.87
Evidence for autoregulation and cell signaling pathway regulation from genome-wide binding of the Drosophila retinoblastoma protein. G3 (Bethesda) (2012) 0.86
A dual role for the dREAM/MMB complex in the regulation of differentiation-specific E2F/RB target genes. Mol Cell Biol (2012) 0.85
Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer. PLoS One (2014) 0.85
Drosophila lin-52 acts in opposition to repressive components of the Myb-MuvB/dREAM complex. Mol Cell Biol (2012) 0.83
Autophagy promotes radiation-induced senescence but inhibits bystander effects in human breast cancer cells. Autophagy (2014) 0.83
Hippo and rassf1a Pathways: A Growing Affair. Mol Biol Int (2012) 0.83
Organ size control is dominant over Rb family inactivation to restrict proliferation in vivo. Cell Rep (2014) 0.82
Mechanism-based screen establishes signalling framework for DNA damage-associated G1 checkpoint response. PLoS One (2012) 0.82
MicroRNA-135b regulates apoptosis and chemoresistance in colorectal cancer by targeting large tumor suppressor kinase 2. Am J Cancer Res (2015) 0.81
dREAM co-operates with insulator-binding proteins and regulates expression at divergently paired genes. Nucleic Acids Res (2014) 0.80
DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome. Front Behav Neurosci (2016) 0.79
An indirect role for ASPP1 in limiting p53-dependent p21 expression and cellular senescence. EMBO J (2011) 0.79
DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis. Mol Cell Oncol (2015) 0.79
Sweet DREAMs for Hippo. Genes Dev (2011) 0.78
MicroRNAs as molecular classifiers for cancer. Cell Cycle (2011) 0.78
Regulation of oncogene-induced cell cycle exit and senescence by chromatin modifiers. Cancer Biol Ther (2012) 0.78
Drosophila as a Potential Model for Ocular Tumors. Ocul Oncol Pathol (2015) 0.77
The association of mammalian DREAM complex and HPV16 E7 proteins. Am J Cancer Res (2015) 0.75
Defining a new vision for the retinoblastoma gene: report from the 3rd International Rb Meeting. Cell Div (2013) 0.75
The Hippo pathway, p53 and cholesterol. Cell Cycle (2016) 0.75
Regulation of cell polarity determinants by the Retinoblastoma tumor suppressor protein. Sci Rep (2016) 0.75
Hippo Pathway: An Emerging Regulator of Craniofacial and Dental Development. J Dent Res (2017) 0.75
The Drosophila LIN54 homolog Mip120 controls two aspects of oogenesis. Biol Open (2017) 0.75
The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ (2017) 0.75
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A (1995) 32.89
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell (1997) 29.13
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05
Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell (2005) 12.73
A network-based analysis of systemic inflammation in humans. Nature (2005) 12.60
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell (2003) 11.40
The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell (2005) 10.61
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88
Rb targets histone H3 methylation and HP1 to promoters. Nature (2001) 8.26
The essence of senescence. Genes Dev (2010) 8.21
Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell (1992) 7.61
A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell (2006) 6.96
The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell (2003) 6.48
A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell (2009) 6.23
The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer (2007) 5.78
Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev (1998) 5.60
Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem (2007) 5.49
The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev (1995) 5.27
Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer (2008) 5.19
Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development (1995) 5.18
TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway. Mol Cell Biol (2008) 5.02
The signals and pathways activating cellular senescence. Int J Biochem Cell Biol (2004) 5.00
Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell (2005) 4.83
From cell structure to transcription: Hippo forges a new path. Cell (2006) 4.65
The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. Cancer Cell (2008) 4.08
Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell (2010) 3.81
Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol Cell Biol (2000) 3.37
PML is induced by oncogenic ras and promotes premature senescence. Genes Dev (2000) 3.35
E2F1 represses beta-catenin transcription and is antagonized by both pRB and CDK8. Nature (2008) 3.24
E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex. Genes Dev (2002) 3.12
The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell (2001) 2.93
Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc Natl Acad Sci U S A (2009) 2.82
Evolutionarily conserved multisubunit RBL2/p130 and E2F4 protein complex represses human cell cycle-dependent genes in quiescence. Mol Cell (2007) 2.74
Kibra is a regulator of the Salvador/Warts/Hippo signaling network. Dev Cell (2010) 2.73
Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol (2011) 2.69
Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat Cell Biol (2006) 2.60
Healing and hurting: molecular mechanisms, functions, and pathologies of cellular senescence. Mol Cell (2009) 2.58
Molecular dissection of formation of senescence-associated heterochromatin foci. Mol Cell Biol (2007) 2.56
Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res (2003) 2.52
RAGE signaling sustains inflammation and promotes tumor development. J Exp Med (2008) 2.51
Many roads lead to oncogene-induced senescence. Oncogene (2008) 2.43
Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol Cell (2005) 2.35
Senescence-associated heterochromatin foci are dispensable for cellular senescence, occur in a cell type- and insult-dependent manner and follow expression of p16(ink4a). Cell Cycle (2011) 2.31
Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res (2008) 2.18
E2F-associated chromatin modifiers and cell cycle control. Curr Opin Cell Biol (2007) 2.04
Kinase requirements in human cells: I. Comparing kinase requirements across various cell types. Proc Natl Acad Sci U S A (2008) 1.95
Remodeling of chromatin structure in senescent cells and its potential impact on tumor suppression and aging. Gene (2007) 1.92
MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene (2003) 1.83
Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene (2003) 1.82
DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev (2011) 1.82
High intensity ras signaling induces premature senescence by activating p38 pathway in primary human fibroblasts. J Biol Chem (2003) 1.76
RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chromosomes Cancer (2006) 1.72
Retinoblastoma tumor suppressor protein-dependent methylation of histone H3 lysine 27 is associated with irreversible cell cycle exit. J Cell Biol (2007) 1.72
Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res (2006) 1.67
Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol Cell Biol (2007) 1.62
E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell (2002) 1.59
An Rb-Skp2-p27 pathway mediates acute cell cycle inhibition by Rb and is retained in a partial-penetrance Rb mutant. Mol Cell (2004) 1.55
Requirement for p27(KIP1) in retinoblastoma protein-mediated senescence. Mol Cell Biol (2001) 1.51
Structure, expression, and chromosome mapping of LATS2, a mammalian homologue of the Drosophila tumor suppressor gene lats/warts. Genomics (2000) 1.40
Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells. Mol Cell (2005) 1.34
Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep (2009) 1.33
Frequent alterations in the expression of serine/threonine kinases in human cancers. Cancer Res (2006) 1.32
Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. Nat Cell Biol (2006) 1.31
Regulation of Rb and E2F by signal transduction cascades: divergent effects of JNK1 and p38 kinases. EMBO J (1999) 1.30
ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci U S A (2001) 1.29
Regulation of E2Fs and senescence by PML nuclear bodies. Genes Dev (2011) 1.25
A G1 checkpoint mediated by the retinoblastoma protein that is dispensable in terminal differentiation but essential for senescence. Mol Cell Biol (2009) 1.23
Mutation rate of MAP2K4/MKK4 in breast carcinoma. Hum Mutat (2002) 1.21
Tyrosine phosphorylation of VHR phosphatase by ZAP-70. Nat Immunol (2002) 1.16
Inhibition of oncogenic transformation by mammalian Lin-9, a pRB-associated protein. EMBO J (2004) 1.15
Cooperation between dE2F1 and Yki/Sd defines a distinct transcriptional program necessary to bypass cell cycle exit. Genes Dev (2011) 1.13
Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Hum Mutat (2006) 1.12
Characterization of cells and gene-targeted mice deficient for the p53-binding kinase homeodomain-interacting protein kinase 1 (HIPK1). Proc Natl Acad Sci U S A (2003) 1.11
Combined inactivation of pRB and hippo pathways induces dedifferentiation in the Drosophila retina. PLoS Genet (2010) 1.10
Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene (2007) 1.08
Inflammatory signaling and cellular senescence. Cell Signal (2008) 1.08
Screens using RNAi and cDNA expression as surrogates for genetics in mammalian tissue culture cells. Cold Spring Harb Symp Quant Biol (2005) 1.08
Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation. Oncogene (2009) 1.06
Stress-activated MAP kinase cascades in cellular senescence. Curr Med Chem (2009) 1.06
The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor. Mol Endocrinol (2004) 1.06
LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma. Lung Cancer (2008) 1.01
Molecular dissection of 17q12 amplicon in upper gastrointestinal adenocarcinomas. Mol Cancer Res (2006) 0.97
NF-kappa B-dependent induction of cyclin D1 by retinoblastoma protein (pRB) family proteins and tumor-derived pRB mutants. J Biol Chem (2003) 0.95
Nucleoside diphosphate kinase Nm23-H1 regulates chromosomal stability by activating the GTPase dynamin during cytokinesis. Proc Natl Acad Sci U S A (2010) 0.94
Induction of premature senescence by hsp90 inhibition in small cell lung cancer. PLoS One (2010) 0.94
BCL6-mediated attenuation of DNA damage sensing triggers growth arrest and senescence through a p53-dependent pathway in a cell context-dependent manner. J Biol Chem (2008) 0.90
Rb protein down-regulates the stress-activated signals through inhibiting c-Jun N-terminal kinase/stress-activated protein kinase. J Biol Chem (2000) 0.90
pRb inactivation in senescent cells leads to an E2F-dependent apoptosis requiring p73. Mol Cancer Res (2003) 0.86
p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways. Oncogene (2000) 0.86
Serine protease Omi/HtrA2 targets WARTS kinase to control cell proliferation. Oncogene (2006) 0.84
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (2004) 11.58
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev (2002) 8.31
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A (2005) 6.82
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72
The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer (2002) 4.48
Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature (2012) 4.35
p120-catenin and p190RhoGAP regulate cell-cell adhesion by coordinating antagonism between Rac and Rho. Cell (2006) 4.24
Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev (2007) 4.11
A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell (2006) 3.78
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature (2011) 3.69
Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev (2008) 3.67
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell (2012) 3.39
Modulation of Rho GTPase signaling regulates a switch between adipogenesis and myogenesis. Cell (2003) 3.36
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal (2010) 3.25
A compendium of potential biomarkers of pancreatic cancer. PLoS Med (2009) 3.00
Proteome-scale purification of human proteins from bacteria. Proc Natl Acad Sci U S A (2002) 2.88
Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res (2007) 2.78
Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Res (2011) 2.71
Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol (2008) 2.69
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther (2008) 2.58
STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res (2011) 2.35
Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res (2007) 2.30
"Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res (2006) 2.30
Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci U S A (2008) 2.27
GAP control: regulating the regulators of small GTPases. Trends Cell Biol (2004) 2.21
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest (2011) 2.20
A-type lamins regulate retinoblastoma protein function by promoting subnuclear localization and preventing proteasomal degradation. Proc Natl Acad Sci U S A (2004) 2.17
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology (2009) 2.17
Kinase requirements in human cells: I. Comparing kinase requirements across various cell types. Proc Natl Acad Sci U S A (2008) 1.95
Rnd proteins function as RhoA antagonists by activating p190 RhoGAP. Curr Biol (2003) 1.84
Mutation of Drosophila Lsd1 disrupts H3-K4 methylation, resulting in tissue-specific defects during development. Curr Biol (2007) 1.83
Opposing functions of TFII-I spliced isoforms in growth factor-induced gene expression. Mol Cell (2006) 1.81
Modeling oncogene addiction using RNA interference. Proc Natl Acad Sci U S A (2008) 1.79
The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta (2006) 1.75
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med (2013) 1.67
Modulation of CREB activity by the Rho GTPase regulates cell and organism size during mouse embryonic development. Dev Cell (2002) 1.58
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget (2011) 1.55
Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res (2009) 1.54
Integrin signaling through Arg activates p190RhoGAP by promoting its binding to p120RasGAP and recruitment to the membrane. Mol Biol Cell (2006) 1.54
Viral perturbations of host networks reflect disease etiology. PLoS Comput Biol (2012) 1.54
Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol (2008) 1.53
SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway. Mol Cell Biol (2004) 1.53
Distinct mechanisms of E2F regulation by Drosophila RBF1 and RBF2. EMBO J (2002) 1.49
Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. Mol Cell (2012) 1.48
A structure-guided approach to creating covalent FGFR inhibitors. Chem Biol (2010) 1.46
Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res (2012) 1.45
p190RhoGAP is the convergence point of adhesion signals from alpha 5 beta 1 integrin and syndecan-4. J Cell Biol (2008) 1.41
Science funding: Provocative questions in cancer research. Nature (2012) 1.36
Inhibition of Rho via Arg and p190RhoGAP in the postnatal mouse hippocampus regulates dendritic spine maturation, synapse and dendrite stability, and behavior. J Neurosci (2007) 1.33
A gradient of epidermal growth factor receptor signaling determines the sensitivity of rbf1 mutant cells to E2F-dependent apoptosis. Mol Cell Biol (2006) 1.31
Adhesion-dependent regulation of p190RhoGAP in the developing brain by the Abl-related gene tyrosine kinase. Curr Biol (2004) 1.30
The CHR promoter element controls cell cycle-dependent gene transcription and binds the DREAM and MMB complexes. Nucleic Acids Res (2011) 1.30
Genetic interactions between Drosophila melanogaster Atg1 and paxillin reveal a role for paxillin in autophagosome formation. Autophagy (2007) 1.30
Isoform-specific ras functions in development and cancer. Future Oncol (2009) 1.29
Building a human kinase gene repository: bioinformatics, molecular cloning, and functional validation. Proc Natl Acad Sci U S A (2005) 1.27
A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation. Oncotarget (2011) 1.26
Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. Bioessays (2007) 1.26
Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion. Cancer Res (2008) 1.26
Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J Biol Chem (2013) 1.25
EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res (2011) 1.24
p190-B RhoGAP regulates mammary ductal morphogenesis. Mol Endocrinol (2003) 1.23
Critical roles for non-pRb targets of human papillomavirus type 16 E7 in cervical carcinogenesis. Cancer Res (2006) 1.21
Thy-1 regulates fibroblast focal adhesions, cytoskeletal organization and migration through modulation of p190 RhoGAP and Rho GTPase activity. Exp Cell Res (2004) 1.20
The Drosophila ATM ortholog, dATM, mediates the response to ionizing radiation and to spontaneous DNA damage during development. Curr Biol (2004) 1.19
Cdh1 regulates cell cycle through modulating the claspin/Chk1 and the Rb/E2F1 pathways. Mol Biol Cell (2009) 1.18
Kinase requirements in human cells: II. Genetic interaction screens identify kinase requirements following HPV16 E7 expression in cancer cells. Proc Natl Acad Sci U S A (2008) 1.17
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res (2010) 1.13
EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors (2012) 1.13
Kinase requirements in human cells: IV. Differential kinase requirements in cervical and renal human tumor cell lines. Proc Natl Acad Sci U S A (2008) 1.12
GAPs in growth factor signalling. Growth Factors (2005) 1.12
High-throughput lung cancer cell line screening for genotype-correlated sensitivity to an EGFR kinase inhibitor. Methods Enzymol (2008) 1.11
Nucleocytoplasmic shuttling of p130/RBL2: novel regulatory mechanism. Mol Cell Biol (2002) 1.10
Disruption of the Fbxw8 gene results in pre- and postnatal growth retardation in mice. Mol Cell Biol (2007) 1.10
Dp1 is required for extra-embryonic development. Development (2003) 1.08
Phospholipids can switch the GTPase substrate preference of a GTPase-activating protein. J Biol Chem (2003) 1.08
High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy. Proc Natl Acad Sci U S A (2011) 1.07
ErbBs in lung cancer. Exp Cell Res (2008) 1.07
Examination of the pRb-dependent and pRb-independent functions of E7 in vivo. J Virol (2005) 1.05
An FF domain-dependent protein interaction mediates a signaling pathway for growth factor-induced gene expression. Mol Cell (2005) 1.05
Regulation of Rho and Rac signaling to the actin cytoskeleton by paxillin during Drosophila development. Mol Cell Biol (2005) 1.05
Crosstalk between the p190-B RhoGAP and IGF signaling pathways is required for embryonic mammary bud development. Dev Biol (2007) 1.04
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res (2006) 1.03
Plakophilin3 downregulation leads to a decrease in cell adhesion and promotes metastasis. Int J Cancer (2008) 1.03
p190A RhoGAP is a glycogen synthase kinase-3-beta substrate required for polarized cell migration. J Biol Chem (2008) 1.03
Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models. Mol Cancer Ther (2013) 1.03
Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. Clin Cancer Res (2008) 1.01